The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia.
We assessed the cerebral protective effects of the competitive interleukin-1 antagonist rhIL-1ra in 7-day-old rats that were subjected to brain hypoxia-ischemia by unilateral carotid artery ligation and subsequent exposure to 2 h of 7.5% O2-balanced N2. This procedure leads to atrophy in the cerebral hemisphere ipsilateral to carotid occlusion, with prominent foci of neuronal infarction in the striatum. Systemic administration of 100 mg/kg of rhIL-1ra before and/or after the hypoxic exposure limited the insult. The results indicate that rhIL-1ra has potent neuroprotective properties against morphologic brain injury from hypoxia-ischemia. rhIL-1ra may prove to be clinically useful in protecting against hypoxia-ischemia-related disorders.
Martin
D
D
Department of Pharmacology, Synergen, Inc., Boulder, Colorado 80301.
Chinookoswong
N
N
Miller
G
G
D000818:Animals; D002545:Brain Ischemia / Q000473:pathology; D002544:Cerebral Infarction / Q000473:pathology*; D003342:Corpus Striatum / Q000473:pathology; D005260:Female; D000860:Hypoxia / Q000473:pathology; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D011994:Recombinant Proteins
D018696:Neuroprotective Agents; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins